Ventas’s balanced business model, portfolio diversification, and financial strength power our long-term sustained delivery of superior, reliable returns. Since 2000, our compound annual total shareholder return of 23% far outpaced the S&P 500, as we delivered total return of 5,342%.
Based on annual cash dividends paid from 2001 through 2018.
As one of the world’s foremost real estate investment trusts (REIT), Ventas, Inc., an S&P 500 company, is the premier capital provider to leading seniors housing, healthcare companies and research institutions. A carefully-curated, diverse portfolio of approximately 1,200 properties combined with our highly-focused strategy, financial strength and experienced team has delivered consistent outstanding performance for two decades.
Ventas has announced four new developments totaling approximately $0.8 billion in its university-based Research & Innovation (“R&I”) business, all in partnership with Wexford Science & Technology, LLC (“Wexford”), the leading developer of university-focused real estate solutions.
These outstanding developments with leading institutions include:
1) Creation of a research, academic medicine and innovation hub anchored by a new relationship with University of Pittsburgh to house ground-breaking immunotherapy research in collaboration with the University of Pittsburgh Medical Center (“UPMC”) and co-located with UPMC’s Shadyside Hospital
2) A new development that expands the flourishing Philadelphia uCity Square Knowledge Community associated with the University of Pennsylvania
3) A state of the art College of Nursing and Health Professionals for Drexel University, also in uCity Square
4) Expansion of the vibrant Cortex Innovation Community associated with Washington University in St. Louis
These investments are part of the near-term $1.5 billion R&I pipeline of expected new projects previously announced by Ventas.